Company Overview
About Alumis
Alumis is a South San Francisco-based clinical-stage biopharmaceutical company founded in 2021 by Martin Babler and Joseph Arol, with a focus on developing precision oral therapies for patients with serious immune-mediated diseases. The company's lead program, ESK-001, is a highly selective TYK2 (tyrosine kinase 2) inhibitor targeting conditions including moderate-to-severe plaque psoriasis, systemic lupus erythematosus (SLE), and inflammatory bowel disease. TYK2 inhibition is a validated immunology mechanism — Bristol Myers Squibb's Sotyktu (deucravacitinib) was the first approved TYK2 inhibitor — and Alumis is developing what it believes is a next-generation molecule with improved selectivity.
Business Model & Competitive Advantage
Alumis completed an initial public offering on the Nasdaq stock exchange in June 2024 under the ticker symbol ALMS, raising capital to fund Phase 2 and Phase 3 clinical trials. Prior to the IPO, the company raised over $400M in private funding from investors including a16z Bio + Health, Foresite Capital, RA Capital Management, and others. The company's precision analytics platform combines genomic, biomarker, and clinical data to identify patient subpopulations most likely to respond to TYK2 inhibition — enabling smarter trial design and potential companion diagnostic development.
Competitive Landscape 2025–2026
Alumis competes in the high-value immunology market alongside established biologics (Humira, Skyrizi, Dupixent) and the growing class of oral small molecules (Sotyktu, JAK inhibitors). Its differentiation thesis is that ESK-001 can deliver biologic-comparable efficacy in an oral pill format with a potentially better safety profile than JAK inhibitors, which carry FDA black box warnings. Success in psoriasis could pave the way for label expansions into lupus and IBD — both large, underserved markets.
Key Differentiators
Emerging Innovator
Alumis is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
10x Genomics
10x Genomics was founded in 2012 in Pleasanton, California by Serge Saxonov, Ben Hindson, and Kevin Ness. The company developed the Chromium platform for single-cell RNA sequencing (scRNA-seq), enabli
Karius
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens
Compare Alumis with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Alumis? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Alumis Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Alumis vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →